Overview

ROXRO PHARMA, Inc. is a privately owned, virtually organized specialty pharmaceutical company focused on developing innovative treatments for pain.

Founded in 1999, ROXRO was one of the first pharmaceutical start-ups built upon the “virtual company” business model. Led by a highly experienced senior management team, ROXRO has assembled a global network of external experts to successfully bring its products through all aspects of development.

ROXRO is focused on treating acute pain so that patients can rapidly return to their normal lives. Our products include:

Sprix™: ROXRO filed a New Drug Application (NDA) for their lead candidate Sprix™ (formerly ROX-888) which was accepted by the FDA for full review. A PDUFA date has been set for October 5, 2009. Sprix™ is an intranasal formulation of the widely used injectable analgesic ketorolac. ROXRO also has successfully completed two Phase 2 trials of Sprix™ for the treatment of dental and postoperative pain. These results demonstrate the compound’s ability to effectively treat acute moderate-to-severe pain without the disabling side effects commonly associated with opioid analgesics.

ROX-828: Currently in Phase 2 clinical development, ROX-828 is an alternative intranasal formulation of ketorolac for the treatment of migraine.